Abstract:Background: The incidence of primary liver cancer is increasing year by year. In 2022 alone, more than 900000 people were diagnosed with liver cancer worldwide, with hepatocellular carcinoma (HCC) accounting for 75%-85% of cases. HCC is the most common primary liver cancer. China has the highest incidence and mortality rate of HCC in the world, and it is one of the malignant tumors that seriously threaten the health of Chinese people. The onset of liver cancer is occult, the early cases lack typical clinical symptoms, and most of the patients are already in the middle and late stage when diagnosed. Therefore, it is very important to find new markers for the early detection and diagnosis of liver cancer, improve the therapeutic effect, and improve the prognosis of patients. Protein tyrosine phosphatase non-receptor 2 (PTPN2) has been shown to be associated with colorectal cancer, triple-negative breast cancer, non-small cell lung cancer, and prostate cancer, but its biological role and function in tumors remain to be further studied. Aim: To combine the results of relevant data obtained from The Cancer Genome Atlas (TCGA) to provide the first in-depth analysis of the biological role of PTPN2 in HCC. Methods: The expression of PTPN2 in HCC was first analyzed based on the TCGA database, and the findings were then verified by immunohistochemical staining, quantitative real-time polymerase chain reaction (qRT-PCR), and immunoblotting. The value of PTPN2 in predicting the survival of patients with HCC was assessed by analyzing the relationship between PTPN2 expression in HCC tissues and clinicopathological features. Finally, the potential of PTPN2 affecting immune escape of liver cancer was evaluated by tumor immune dysfunction and exclusion and immunohistochemical staining. Results: The results of immunohistochemical staining, qRT-PCR, and immunoblotting in combination with TCGA database analysis showed that PTPN2 was highly expressed and associated with a poor prognosis in HCC patients. Kyoto Encyclopedia of Genes and Genomes enrichment analysis showed that PTPN2 was associated with various pathways, including cancer-related pathways, the Notch signaling pathway, and the MAPK signaling pathway. Gene Set Enrichment Analysis showed that PTPN2 was highly expressed in various immune-related pathways, such as the epithelial mesenchymal transition process. A risk model score based on PTPN2 showed that immune escape was significantly enhanced in the high-risk group compared with the low-risk group. Conclusion: This study investigated PTPN2 from multiple biological perspectives, revealing that PTPN2 can function as a biomarker of poor prognosis and mediate immune evasion in HCC.

TROVE2 Regulated Invasion and Migration of Hepatocellular Carcinoma Cells Via Heparanase

Infiltrating Regulatory T Cells Promote Invasiveness of Liver Cancer Cells Via Inducing Epithelial-Mesenchymal Transition

NR1D2 Accelerates Hepatocellular Carcinoma Progression by Driving the Epithelial-to-Mesenchymal Transition

R-spondin 2 Promotes Proliferation and Migration Via the Wnt/β-catenin Pathway in Human Hepatocellular Carcinoma.

Oncogene TUBA1C Promotes Migration and Proliferation in Hepatocellular Carcinoma and Predicts a Poor Prognosis.

Tissue Transglutaminase 2 Exerts a Tumor-Promoting Role in Hepatitis B Virus-Related Hepatocellular Carcinoma.

Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma.

Role of UBE2T gene in the migration and invasion of hepatocellular carcinoma cells and its clinical significance

TC2N Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Targeting the Wnt/β-Catenin Signaling Pathway

Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma

Long Noncoding RNA HOST2 Promotes Epithelial-Mesenchymal Transition, Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating the JAK2-STAT3 Signaling Pathway

TLK2 promotes progression of hepatocellular carcinoma through Wnt/β-catenin signaling

Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway

TPX2 Knockdown Suppressed Hepatocellular Carcinoma Cell Invasion Via Inactivating AKT Signaling and Inhibiting MMP2 and MMP9 Expression.

TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway.

MAT2B Mediates Invasion and Metastasis by Regulating EGFR Signaling Pathway in Hepatocellular Carcinoma

Activated Hepatic Stellate Cells Promote Epithelial-to-mesenchymal Transition in Hepatocellular Carcinoma Through Transglutaminase 2-Induced Pseudohypoxia

Expression of Heparanase in Hepatocellular Carcinoma Has Prognostic Significance: a Tissue Microarray Study.

Comprehensive Identification of Trem2 as a Key Factor in Promoting the Progression of Hepatocellular Carcinoma and Predicting Prognosis

Vascular Endothelial Cells Facilitated HCC Invasion and Metastasis Through the Akt and NF-κB Pathways Induced by Paracrine Cytokines

HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment